GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyteir Therapeutics Inc (OTCPK:CYTT) » Definitions » EPS without NRI

Cyteir Therapeutics (Cyteir Therapeutics) EPS without NRI : $-0.92 (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Cyteir Therapeutics EPS without NRI?

Cyteir Therapeutics's earnings per share without non-recurring items for the three months ended in Sep. 2023 was $-0.10. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.92.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -19.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cyteir Therapeutics's EPS without NRI or its related term are showing as below:

CYTT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -19.2   Med: -19.2   Max: -19.2
Current: -19.2

During the past 4 years, Cyteir Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -19.20% per year. The lowest was -19.20% per year. And the median was -19.20% per year.

CYTT's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.4 vs CYTT: -19.20

Cyteir Therapeutics's EPS (Diluted) for the three months ended in Sep. 2023 was $-0.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.94.

Cyteir Therapeutics's EPS (Basic) for the three months ended in Sep. 2023 was $-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.94.


Cyteir Therapeutics EPS without NRI Historical Data

The historical data trend for Cyteir Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyteir Therapeutics EPS without NRI Chart

Cyteir Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
EPS without NRI
-0.77 -0.87 -2.16 -1.31

Cyteir Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.25 -0.33 -0.24 -0.10

Competitive Comparison of Cyteir Therapeutics's EPS without NRI

For the Biotechnology subindustry, Cyteir Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyteir Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cyteir Therapeutics's PE Ratio without NRI falls into.



Cyteir Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyteir Therapeutics  (OTCPK:CYTT) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cyteir Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Cyteir Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyteir Therapeutics (Cyteir Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Executives
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
John F Thero director C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Adam M Veness officer: General Counsel C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Stephen H. Sands director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Jeffrey Humphrey director C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Droia Invest Ii Scsp 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Janwillem Naesens director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Sa Ihl 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Karen Hong director 69 PARKSIDE DRIVE, PRINCETON NJ 08540
Bv Wepaven 10 percent owner BRUSSELSESTEENWEG 11, MEISE C9 1860
Luc Verelst 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Df Ii Gp Sarl 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Timothy Romberger director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Racquel Bracken director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421